Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
Boston Scientific (NYSE:BSX), a medical device maker for interventional specialties, closed Wednesday at $50.42, down 12.53%. The stock dropped after management reiterated soft full-year organic growth guidance and flagged softer demand in key WATCHMAN and urology franchises. Trading volume reached 49.5 million shares, about 191% above its three-month average of 17 million shares. Boston Scientific IPO'd in 1992 and has grown 1,078% since going public.
How the markets moved today
S&P 500 inched up 0.03% to 7,521, while the Nasdaq Composite added 0.07% to finish at 26,675. Within medical devices, industry peers Abbott Laboratories closed at $85.68 (-1.14%) and Stryker ended at $305.99 (-2.24%), reflecting broader pressure across sector rivals.
What this means for investors
Investors were hoping for a positive update from Boston Scientific at the Bernstein Annual Strategic Decisions Conference today, but management merely reiterated its previous guidance for the year. The company projects that organic sales will rise between 5.5% to 7% in 2026 and by 6% to 8% in Q2. However, due to expectations for its key WATCHMAN device to deliver flat sequential sales growth in Q2 and Q3, analysts believe the lower end of this guidance may be more realistic.
While the WATCHMAN device was supposed to be a core growth driver for the company, it remains the market share leader in its niche despite its growth slowdown. Trading at 15 times forward earnings after its stock has been halved, BSX stock and its broad portfolio of medical devices aren’t outrageously valued.
Should you buy stock in Boston Scientific right now?
Before you buy stock in Boston Scientific, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Boston Scientific wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,852!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,317,207!*
Now, it’s worth noting Stock Advisor’s total average return is 984% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 27, 2026.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
Recommended Articles
